Boston Children’s Hospital announced today that it partnered with ElevateBio for a five-year cell and gene therapy advancement program.
The collaborative agreement will seek to advance cell and gene therapy programs originating out of Boston Children’s Hospital with an introduction to Boston Children’s translational research capabilities.
Cambridge, Ma.-based ElevateBio will offer Boston Children’s researchers access to its core-enabling technologies, manufacturing and expertise to help advance the programs, with a guarantee of dedicated viral-vector manufacturing space at its BaseCamp centralized R&D manufacturing center, according to a news release.
Additionally, under the agreement, ElevateBio pledged to offer sponsored research agreements with Boston Children’s investigators as part of the company formation process.
“At Boston Children’s Hospital, we are proud of the foundation we’ve established as a leading innovator in cell and gene therapy, so collaborating with ElevateBio – a company so well-positioned to change the face of cell and gene therapy forever – is a natural fit into our overall vision,” Boston Children’s Hospital chief of hematology/oncology Dr. David Williams said in the release. “Using ElevateBio’s world-class enabling technologies, this alliance will help catalyze the science being conducted in the labs across Boston Children’s, moving potential treatments into the clinic and accelerating the development of multiple cell and gene therapy platforms.”
ElevateBio chairman & CEO David Hallal noted that Boston Children’s history of work in cell and gene therapy has helped to spin-out companies with groundbreaking technologies.
“At ElevateBio, we have built unique end-to-end capabilities that leverage our suite of enabling technologies, technologic know-how, and world-class expertise to advance our own innovative cell and gene therapies as well as accelerate those of industry and academic collaborators,” Hallal said. “Through this collaboration, we’re excited to work with the team at Boston Children’s to form new companies, the first of which we’ve identified and will announce later this year, and also enable access to our cutting-edge viral vector manufacturing facilities that will help Boston Children’s researchers move their therapies through development more efficiently.”
